Cover Image
市場調查報告書

真性紅血球增生後骨髓纖維化 (PPV-MF):開發中產品分析

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251623
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
真性紅血球增生後骨髓纖維化 (PPV-MF):開發中產品分析 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 102 Pages
簡介

所謂真性紅血球增生症(PC, PCV)是骨髓過度製造紅血球的骨髓增殖性血癌。也有引發過度製造出白血球及血小板的可能性。其症狀有心臟病發作、心臟麻痺、深部靜脈血栓症(DVT)、頭痛、缺乏集中力及疲勞。這個疾病有可能藉由化療,輸血,移植及藥物療法加以控制。

本報告提供真性紅血球增生後骨髓纖維化 (PPV-MF)治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

真性紅血球增生後骨髓纖維化 (PPV-MF)的概要

治療藥的開發

  • 開發中產品的概要

真性紅血球增生後骨髓纖維化 (PPV-MF) :企業開發中的治療藥

真性紅血球增生後骨髓纖維化 (PPV-MF) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

真性紅血球增生後骨髓纖維化 (PPV-MF) :企業開發中的產品

真性紅血球增生後骨髓纖維化 (PPV-MF)的治療藥開發企業

  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • JW Pharmaceutical Corporation
  • MEI Pharma, Inc.
  • 日本新藥
  • Novartis AG
  • Pfizer Inc.
  • Promedior, Inc.

真性紅血球增生後骨髓纖維化 (PPV-MF) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

真性紅血球增生後骨髓纖維化 (PPV-MF) :最近的開發平台趨勢

真性紅血球增生後骨髓纖維化 (PPV-MF) :暫停中的計劃

真性紅血球增生後骨髓纖維化 (PPV-MF) :中止開發的產品

真性紅血球增生後骨髓纖維化 (PPV-MF) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8511IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 9, 3 and 1 respectively for Post-Polycythemia Vera Myelofibrosis (PPV-MF).

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview
  • Therapeutics Development
    • Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
    • Celgene Corporation
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Incyte Corporation
    • Italfarmaco S.p.A.
    • JW Pharmaceutical Corporation
    • MedImmune, LLC
    • MEI Pharma, Inc.
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Pfizer Inc.
    • Promedior, Inc.
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CWP-291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idelalisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • momelotinib dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRM-151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vismodegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corporation, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corporation, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MedImmune, LLC, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma, Inc., H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc., H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H2 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top